title: Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
authors.affiliation: Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892-1202, USA.
authors.forename: Robert Quan
authors.initials: RQ
authors.lastname: Le
authors.forename: Margaret
authors.initials: M
authors.lastname: Bevans
authors.forename: Bipin N
authors.initials: BN
authors.lastname: Savani
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Mitchell
authors.forename: Kate
authors.initials: K
authors.lastname: Stringaris
authors.forename: Eleftheria
authors.initials: E
authors.lastname: Koklanaris
authors.forename: A John
authors.initials: AJ
authors.lastname: Barrett
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D017741:Survivors; D016896:Treatment Outcome; D055815:Young Adult